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Introduction
Th e value of glucocorticoid therapy was discovered 
65 years ago. In 1949, Philip Hench reported the dramatic 
eﬀ ect of compound E on rheumatoid arthritis (RA) [1]. 
Nowadays, glucocorticoids play a pivotal role in the 
management of many inﬂ ammatory rheumatic diseases 
[2-7]. Glucocorticoids represent the most frequently 
em ployed class of anti-inﬂ ammatory drugs, with a rise in 
use in recent years [8-11], despite the development of 
new treatment modalities such as biological drugs appli-
cable for many rheumatic diseases. Community survey 
data indicate use of glucocorticoids among 0.5% of the 
general population, and 1.4% of women aged older than 
55 years [12,13]. Between 14.6 and 90% of patients with 
RA worldwide are undergoing treatment with gluco corti-
coids [10]. Almost all patients with polymyalgia rheu-
matic, giant cell arteritis and systemic vasculitis use 
systemic glucocorticoids.
Glucocorticoids are very eﬀ ective anti-inﬂ ammatory 
and immunosuppressive drugs, but their use is restrained 
by fear for and occurrence of adverse eﬀ ects (Figure 1).
Mechanisms of action
Th e eﬀ ects of glucocorticoids are thought to be mediated 
by diﬀ erent mechanisms [14-19]. Classic genomic 
mecha nisms leading to changes in gene expression are 
most important in low-dose therapy (see Figure 2) [20]. 
Th ese actions occur after passage of glucocorticoid 
molecules through the cell membrane, binding to the 
inactive cytosolic glucocorticoid receptor, formation of 
an activated glucocorticoid–cytosolic glucocorticoid 
receptor complex, and translocation of this complex into 
the nucleus. Transactivation and transrepression can be 
initiated in the nucleus. Transactivation is caused by 
binding of two activated glucocorticoid–cytosolic gluco-
corticoid receptor complexes as a dimer to the promotor 
of glucocorticoid-regulated genes, which leads to up-
regulation of the synthesis of certain regulatory proteins 
by transcriptional activation. In transrepression, gluco-
corti coid–cytosolic glucocorticoid receptor monomer 
com plexes interfere with the activity of (proinﬂ am-
matory) trans cription factors such as activator protein 1 
and nuclear factor-κB, leading to downregulation of (pro-
inﬂ am matory) protein synthesis. Genomic processes 
require at least 30  minutes before changes can be 
observed in regulatory protein synthesis, but usually it 
will take hours to days for changes to occur at the cell, 
tissue or organ level [18,21].
Th e repressive, anti-inﬂ ammatory eﬀ ects of gluco corti-
coids were believed until recently to be based mainly on 
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transrepression [19], whereas the negative eﬀ ects – with 
the exception of infection risk – and metabolic actions of 
glucocorticoid therapy were based on transactivation. 
Th is view has been somewhat revised, with the sugges-
tion that some key anti-inﬂ ammatory actions of 
glucocorticoids are caused by gene activation [19,22]. 
Moreover, research in a mouse strain with a deﬁ ciency in 
forming dimer glucocorticoid–glucocorticoid receptor 
complexes, and thus with a transactivation deﬁ ciency, 
showed – along with a failure of glucocorticoids to exert 
a full anti-inﬂ ammatory response  – classic side eﬀ ects 
such as osteoporosis in these mice [23].
In very high-dose therapy, nongenomic mechanisms 
also occur, eﬀ ects of which are evident within minutes 
[20]. Th ese nongenomic mechanisms are mediated via 
the cytosolic glucocorticoid receptor, via the membrane-
bound glucocorticoid receptor, and via nonspeciﬁ c inter-
actions with membranes of cells and organelles, including 
those of mitochondriae.
Th e size of genomic eﬀ ects of glucocorticoid prepara-
tions deﬁ nes their dose equivalence. Dexamethasone and 
betamethasone are the most potent preparations, 
followed by methylprednisolone, predniso(lo)ne, cortisol 
and cortisone [20]. Dosages of speciﬁ c glucocorticoid 
preparations often are expressed in relation to the 
potency of the most frequently used preparation; that is, 
prednisone. Th e deﬁ nitions of low-dose therapy through 
to pulse therapy are presented in Table 1.
Patterns of glucocorticoid use
Glucocorticoid use (dose, duration, administration) 
depends on the diagnosis, indications for glucocorticoid 
therapy, and the goal of treatment (see Table  2). Th e 
therapeutic eﬀ ects range from pain relief in arthritides, to 
disease-modifying eﬀ ects in early RA, and to strong 
immunosuppressive actions in vasculitides and systemic 
lupus erythematosus (SLE). Not all eﬀ ects have been 
studied in detail.
Figure 1. Eff ects of glucocorticoids. Glucocorticoid therapy is associated with both benefi cial eff ects (upper part) and adverse eff ects (lower 
part). CNS, central nervous system; DMARD, disease-modifying antirheumatic drug; HPA, hypothalamic–pituitary–adrenal; NSAID, nonsteroidal anti-
infl ammatory drug; RA, rheumatoid arthritis. Adapted from [127].
van der Goes et al. Arthritis Research & Therapy 2014, 16(Suppl 2):S2 
http://arthritis-research.com/content/16/S2/S2
Page 2 of 13
Primary immunosuppressive treatment with glucocorticoids
Glucocorticoids are anchor drugs for therapeutic strate-
gies in myositis, polymyalgia rheumatica and systemic 
vasculitis. For other rheumatic diseases, glucocorticoids 
are adjunctive therapy, or are not used at all. Mono-
therapy with glucocorticoids is applied in polymyalgia 
rheumatica; remission can often be achieved with 
treatment starting at 15  mg prednisone or equivalent 
daily [24].
Glucocorticoids also represent the most important 
class of drugs in giant cell arteritis. For this disease, 
higher initial dosages are often used (mostly 40 to 60 mg 
prednisone or equivalent daily). Furthermore, in the case 
of (transient) acute visual loss, pulse therapy is applied.
In the treatment of polymyalgia rheumatica and giant 
cell arteritis, other immunomodulatory drugs are some-
times added to glucocorticoids as glucocorticoid-sparing 
agents to decrease the dose or duration of glucocorticoid 
therapy. However, the results of research into the gluco-
corticoid-sparing properties of other immuno suppressive 
medication – that is, use of other agents to decrease the 
cumulative glucocorticoid dose  – are not convincing. 
Outcomes of randomized controlled trials in polymyalgia 
rheumatica on the glucocorticoid-sparing eﬀ ects of 
methotrexate [25-27], azathioprine [28] and inﬂ iximab 
[29] were conﬂ icting. Th e same holds true for adjunctive 
treatment with methotrexate [30-32], cyclo sporine [33], 
etanercept [34] and inﬂ iximab [35] in giant cell arteritis. 
A recent retrospective study in 23 patients indicated that 
leﬂ unomide is eﬀ ective as a glucocorticoid-sparing agent 
in patients with diﬃ  cult-to-treat giant cell arteritis and 
polymyalgia rheumatic, but this still needs to be 
conﬁ rmed in randomized controlled trials [36].
Combination therapy including glucocorticoids
Pulse therapy
Acute episodes or particularly severe forms of rheumatic 
diseases and speciﬁ c complications are indications for 
pulse therapy. In collagen disorders, pulse therapy is 
Figure 2. Genomic action of glucocorticoids. Glucocorticoid binds to the glucocorticoid receptor (GCR) in the cytoplasm. This complex migrates 
into the nucleus. Activation of transcription (transactivation) by binding of GCR–glucocorticoid complex dimers to glucocorticoid-responsive 
elements of DNA upregulates synthesis of regulatory proteins, thought to be responsible for metabolic eff ects and also some anti-infl ammatory/
immunosuppressive eff ects. Interaction of GCR–glucocorticoid complex monomers with proinfl ammatory transcription factors, such as activator 
protein-1, interferon regulatory factor-3 and nuclear factor (NF)-κB, leads to inhibition of binding of these transcriptional factors to their DNA 
consensus sites (for NF-κB: NF-κB-responsive elements). The transcription of these proinfl ammatory transcription factors is thus repressed. This 
process is called transrepression and downregulates synthesis of predominantly infl ammatory/immunosuppressive proteins. Adapted from [128].
Table 1. Defi nition of conventional terms for 
glucocorticoid dosages
Dose Defi nition
Low  ≤7.5 mg prednisone equivalent/day
Medium  >7.5 mg but ≤30 mg prednisone equivalent/day
High  >30 mg but ≤100 mg prednisone equivalent/day
Very high  >100 mg prednisone equivalent/day
Pulse therapy ≥250 mg prednisone equivalent/day for 1 day or a few days
Adapted from [20].
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applied for disease induction or treatment of ﬂ ares. In 
RA, pulse therapy is used to treat serious complications 
of the disease and to induce remission in active disease. 
In the latter, it makes sense to simultaneously start a new 
second-line antirheumatic treatment aiming at stabilizing 
the remission induced by pulse therapy, since the 
beneﬁ cial eﬀ ects generally last about 6 weeks [37]. Th ere 
are several diﬀ erent schemes of pulse therapy. Pulse 
therapy with schemes of 1,000  mg methylprednisolone 
intravenously has proven eﬀ ective in many studies.
High and medium doses
In systemic vasculitis, high-dose glucocorticoids are the 
cornerstone of induction therapy and the therapy of 
ﬂ ares. Usually, other immunosuppressive drugs are 
applied simultaneously. In this chronic treatment, the 
dosages (often starting with 1  mg/kg body weight 
prednisone equivalent) are gradually reduced in weeks to 
months to a maintenance therapy of low to medium dose.
Another application of high-dose glucocorticoids is 
intermittent treatment; for example, in gout to treat 
attacks. In a gout attack, treatment with 35  mg pred ni-
sone during 5  days improved pain scores, as did 
treatment with naproxen [38]. Glucocorticoids are 
stopped in the periods between these attacks, although 
there are a few exceptions. For example, glucocorticoids 
can be used in patients with gout as a bridge for adequate 
suppression of uric acid in cases where nonsteroidal anti-
inﬂ ammatory drugs (NSAIDs) and colchicine are 
contra indicated.
Low dose
Chronic glucocorticoid therapy in RA is often started 
and maintained at a low dose, mostly in addition to other 
disease-modifying antirheumatic drugs. Glucocorticoid 
therapy is highly eﬀ ective for relieving symptoms in 
patients with active RA in the short and medium term 
[39,40]. Improvement has been documented for all 
clinical parameters, including pain scales, joint scores, 
morning stiﬀ ness and fatigue, but also in parameters of 
the acute phase reaction (that is, erythrocyte sedi men-
tation rate and C-reactive protein). Use of a modiﬁ ed-
release preparation at bedtime (that is, releasing the 
administered glucocorticoid in the early morning, similar 
to the circadian rhythms of endogenous cortisol) leads to 
even more improvement in morning stiﬀ ness than use of 
a conventional tablet of equal dosage taken after 
awakening [41]. After 6 months of therapy, the beneﬁ cial 
eﬀ ects of glucocorticoids in general seem to diminish. 
However, clinical experience suggests that if this therapy 
Table 2. General use of glucocorticoids in rheumatology
   Initial oral dose  Intravenous,  
     very high dose Intra-articular
  Low Medium High or pulse therapy injection
Arthritides
 Gouty arthritis, acute – 2 2 – 2
 Juvenile idiopathic arthritis – 1 1 – 1
 Osteoarthritis – – – – 1
 Acute calcium pyrophosphate crystal arthritis – – – – 2
 Psoriatic arthritis – 1 – – 2
 Reactive arthritis – – – – 1
 Rheumatic fever – 1 1 – –
 Rheumatoid arthritis 2 2 1 1 2
Collagen disorders
 Dermatomyositis, polymyositis – – 3 1 –
 Mixed connective tissue disease – 1 – 1 1
 Polymyalgia rheumatica – 3 – 1 –
 Sjögren’s syndrome, primary – – 1 – –
 Systemic lupus erythematosus – 2 1 1  –
 Systemic sclerosis – 1 – – –
Systemic vasculitides
 In general – – 3 1 –
Initial dose, the dose at the start of therapy, will often be decreased in time depending on disease activity: low, ≤7.5 mg prednisone equivalent/day; medium, >7.5 but 
≤30 mg prednisone equivalent/day; high, >30 but ≤100 mg prednisone equivalent/day; very high, >100 mg prednisone equivalent/day. –, rare use; 1, infrequent use, 
for therapy-resistant disease, complications, severe fl are, major exacerbation, and for bridging the lag-time of recently started therapy; 2, frequently added to/used as 
the basic therapeutic strategy; 3, basic part of the therapeutic strategy. With permission from BMJ publishing group [129].
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is then tapered oﬀ  and stopped, some patients experience 
clear aggravation of symptoms and signs, indicating that 
the beneﬁ cial eﬀ ect was still present before tapering. In 
reports, very low doses of glucocorticoids (that is, <5 mg 
prednisone equivalent/day) can be suﬃ  cient for patients 
to remain in remission without causing severe adverse 
events [42]. However, the risk–beneﬁ t ratio of this 
therapy with very low doses has not been studied in a 
prospective randomized way.
Recent studies have (re)established the disease-modify-
ing potential of low-dose glucocorticoids in early RA and 
have renewed the debate on beneﬁ ts and risks of this 
treatment [43-52]. Beneﬁ cial eﬀ ects of initial gluco corti-
coid treatment during the ﬁ rst 2 years of the disease on 
retardation of joint damage are still present after 4 to 
5 years [53-55], which has not been shown for any other 
disease-modifying antirheumatic drug. As such, gluco-
corti coids can be used for helping to achieve remission 
and prevent joint damage in the long term; they are part 
of the management for early RA according to European 
guidelines [56]. Surprisingly, evidence for the eﬃ  cacy of 
glucocorticoids was not incorporated in the 2012 update 
of the American College of Rheumatology treatment 
recommendations for RA [57], which is highly debatable 
[58].
Local application of glucocorticoids
Another type of use is local application of glucocorticoids. 
In persisting nonbacterial arthritis of a joint, intra-
articular glucocorticoid injection can be considered. Th e 
eﬀ ect depends on several factors, such as the treated joint 
(size, weight bearing, or non-weight bearing), the activity 
of arthritis and the volume of synovial ﬂ uid in the treated 
joint, the application of arthrocentesis (synovial ﬂ uid 
aspiration) before injection, the choice and dose of the 
glucocorticoid preparation, the injection technique, and 
application of rest to the injected joint [59].
Among the injectable glucocorticoids, triamcinolone 
hexacetonide is the least soluble preparation and showed 
the longest eﬀ ect [60]. In a randomized controlled study, 
bed rest for 24 hours following injection of a knee joint in 
patients with inﬂ ammatory arthritis resulted in pro-
longed duration of clinical response and reduced the 
need for additional injections, compared with a control 
group that received no particular advice about activity 
with the injected joint [61]. Favorable eﬀ ects of resting 
the injected joints (for example, by splinting in a cast or 
plaster) for 3 weeks in the case of a non-weight bearing 
(upper extremity) joint and 6 weeks for a weight bearing 
(lower extremity) joint have been described [62]. Based 
on the literature, no deﬁ nite evidence-based recom men-
dation can be made, but it seems prudent to rest and 
certainly not to overuse the injected joint for several 
days, even if pain is relieved [63].
An alternative to glucocorticoid therapy for intra-
articular use has not yet been recognized.
Adverse eff ects
Th ere is no doubt that glucocorticoids have a high 
potential for frequent and serious adverse events. Com-
pared with other antirheumatic agents, glucocorticoids 
have a low incidence of short-term symptomatic toxicity 
and patients uncommonly discontinue therapy for this 
reason. Th ere are multiple indications that adverse eﬀ ects 
are more frequent with longer use of glucocorticoids and 
use of higher dosages [64,65], but high-quality data on 
the occurrence of adverse eﬀ ects are scarce especially for 
dosages above 10  mg prednisone daily. Most published 
studies on gluco corticoid toxicity are retrospective and 
observational [66]. Systematic reviews and randomized 
controlled trials are considered the highest quality 
evidence, but these studies are often focused on 
treatment eﬃ  cacy. Th ey have not been powered or 
designed to assess toxicity. Th e inability to diﬀ erentiate 
unfavorable outcomes attribu table to glucocorticoids 
from those occurring as a complication of the disease 
treated or as co-morbidities also confounds the picture. 
Furthermore, there is strong selection bias for gluco-
corticoid use because physicians are inclined to treat 
patients with more severe disease with (higher dosages 
of ) glucocorticoids (confounding by indication).
Th erefore, despite over 60 years of use, robust data on 
toxicities of long-term glucocorticoid therapy are sorely 
lacking [67-70]. Fortunately, many of the adverse events 
can be avoided or dealt with if glucocorticoids are used 
prudently. An overview of positive as well as negative 
eﬀ ects of glucocorticoid therapy is given in Figure 1.
In the following paragraphs, several notorious adverse 
eﬀ ects of glucocorticoid therapy are discussed. Th ese 
paragraphs will give an overview of frequently reported 
adverse eﬀ ects in literature. Additionally, we will discuss 
the inﬂ uence of disease and treatment scheme on the 
occurrence of adverse eﬀ ects.
Eff ects on bone
Osteoporosis
Chronic oral treatment with more than 5 mg prednisone 
daily can lead to a reduction in bone mineral density and 
an increase in the risk of fracture [71]. However, in many 
studies concerning glucocorticoid-induced osteoporosis, 
no attention is paid to the fact that glucocorticoids are 
usually prescribed for inﬂ ammatory diseases, which 
themselves have negative impact on bone mineral 
density.
Bone mineral density changes may develop in RA in 
the absence of glucocorticoid therapy. Previous ﬁ ndings 
suggest that bone loss in RA patients not on gluco-
corticoid therapy mainly occurs during the ﬁ rst months 
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of disease [72,73]. Correlations with parameters of 
inﬂ ammation have been found in some studies [74-77]. 
Development of osteo porosis can thus also be caused by 
active early RA. In early RA, glucocorticoids have 
positive eﬀ ects on bone [43,44,46-51]. Th e joint-sparing 
eﬀ ect is probably based on the inhibition of 
proinﬂ ammatory cytokines such as interleukin-1 and 
tumor necrosis factor [78,79], which have direct positive 
eﬀ ects on osteoclast formation and stimulate osteoblasts 
and T lymphocytes to produce receptor activator of 
nuclear factor-κB ligand [78,80]. Binding of receptor 
activator of nuclear factor-κB ligand to its receptor 
(receptor activator of nuclear factor-κB) on osteoclast 
precursor cells leads to diﬀ erentiation and activation of 
osteoclasts, and subsequently to bone resorption, 
periarticular osteopenia, and formation of bone erosions 
in patients with RA (see Figure  3) [78]. A recent study 
showed that the bone mineral density scores in the ﬁ rst 
years of treatment with low-dose glucocorticoids are 
similar to these scores in patients without glucocorticoid 
therapy, when preventive medication for osteoporosis 
has been used [77]. Preventive measures will be discussed 
in the section ‘Recommendations for clinical practice’.
Osteonecrosis
For adverse eﬀ ects on bone other than osteoporosis, a 
major limitation is that trials have not been powered or 
designed to assess toxicity or long-term eﬀ ects, and 
therefore uncertainty of the true incidence and relevance 
of these adverse eﬀ ects still remains. In general, 
osteonecrosis does not occur frequently. Th e frequency 
of occurrence clearly depends on the dose of gluco-
corticoid therapy and the underlying disease. Regarding 
pulse therapy, osteonecrosis seems to be a more frequent 
side eﬀ ect in patients with SLE compared with patients 
with RA [81]. Both the disease and glucocorticoids 
therefore seem to play a role in osteonecrosis (especially) 
in SLE.
Endocrine eff ects
Weight gain and moon face
In the case of long-term endogenous or exogenous 
glucocorticoid excess, patients can experience increased 
appetite. As a consequence, this may contribute to 
increased body and trunk fat, ﬁ nally leading to a 
cushingoid appearance with centripetal fat accumulation 
and thin extremities with atrophic skin and contusions. A 
recent trial in RA with 10 mg prednisone daily showed a 
small but signiﬁ cant gain in weight over 2 years, with a 
mean of 2.9 kg in the methotrexate-based strategy group 
treated with prednisone compared with 1.3  kg in the 
methotrexate-based strategy group treated with placebo-
prednisone [52]. Additional analyses showed that this 
body weight gain after treatment of active RA was, at 
least partly, regaining patients’ previous weight by the 
reduction of the weight loss-inducing disease activity, 
which was more reduced in the prednisone strategy 
group [82].
Th e incidence of iatrogenic Cushing’s syndrome is 
dependent on dose and duration of therapy. Development 
of a moon face is uncommon in therapy with sub-
physiologic dosages.
Diabetes and cardiovascular disease
Many doctors and patients are afraid of the development 
of diabetes during glucocorticoid therapy [83], and of the 
thereby increasing risk of cardiovascular events [84]. 
Cardiovascular disease is more prevalent in rheumatic 
patients than in the general population [85]. Th is 
increased prevalence is probably based on elevated levels 
of proinﬂ ammatory cytokines such as tumor necrosis 
factor alpha and interleukin-6 in the systemic circulation, 
with multiple eﬀ ects on organs, including adipose tissue, 
and endothelium [86]. Th ese cytokines are also over-
produced in dysfunctional adipose tissue of obese 
individuals [87]. Th e resulting cascade of changes 
throughout the body driven by systemic inﬂ ammation 
leads to a pro-atherogenic proﬁ le: atherogenic lipid 
abnormalities, oxidative stress, deple tion of endothelial 
progenitor cells associated with impairment of vascular 
injury repair, increased arterial stiﬀ ness, insulin resis-
tance, endothelial dysfunction, a hypercoagulable state, 
elevated homocysteine levels, and upregulation of 
athero genic T cells [86].
In RA and SLE, markers of inﬂ ammation correlate with 
impaired insulin sensitivity and impaired beta-cell 
function [88-90]. Deterioration of glucose tolerance has 
not been observed for short-term glucocorticoid therapy 
at medium to high doses [91], which might be explained 
by the eﬀ ectiveness of glucocorticoids in dampening the 
inﬂ ammation. Th e inﬂ uence of glucocorticoid therapy at 
low to medium doses for multiple years on glucose 
metabolism seemed to be minor [92]. Based on these 
studies, one could conclude that glucocorticoids, if used 
to eﬀ ectively treat an inﬂ ammatory condition, are not an 
important risk factor for the development of cardio-
vascular disease. However, in cases of overt diabetes 
before treatment, patients should be instructed to 
carefully monitor their blood glucose level shortly after 
starting glucocorticord therapy [69].
Suppression of the hypothalamic–pituitary–adrenal axis
Administration of glucocorticoids leads to negative feed-
back on the hypothalamus and pituitary glands, resulting 
in less secretion of corticotropin-releasing hormone and 
adrenocorticotropic hormone, respectively. As a result, 
the cortisol secretory capacity of the fasciculate–
reticularis zone of the adrenal cortex may decrease, since 
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this inner cortical zone of cortisol production is 
dependent on adrenocorticotropic hormone for structure 
and function.
Prediction of the suppression of the hypothalamic–
pituitary–adrenal axis and tertiary adrenal insuﬃ   ciency 
is not reliable, but their prevalence appears to depend on 
both the dose and duration of glucocorticoid treatment. 
In the case of long-term glucocorticoid therapy of up to 
10  mg prednisone or equivalent daily, the risk of 
symptomatic adrenal failure is not high, but also not 
negligible. In clinical practice, it seems appropriate to 
anticipate potential adrenal insuﬃ  ciency in patients who 
received 7.5  mg prednisone or equivalent for at least 
3  weeks. Acute cessation of therapy could lead to 
problems. Gradual tapering of the glucocorticoid dose is 
therefore usually applied. In the case of suspected adrenal 
insuﬃ  ciency, adrenocorticotropic hormone stimulation 
testing can help in evaluating the adrenal response [93]. 
Further, in the case of acute injury or stress (for example, 
with surgery), adequate adaptation of the glucocorticoid 
dose is important. Often a temporary increase of the 
dose to 15 mg prednisone equivalent/day is suﬃ  cient for 
minor surgery.
Infections
Randomized clinical trials with glucocorticoids often 
report a not increased risk of infection [44,46,52,94,95]. 
However, cohort studies and case–control studies 
showed an increased occurrence of infections in patients 
with RA [96-99]. Moreover, the dose of glucocorticoid 
therapy and combination treatment with other immuno-
suppressive drugs further elevate the risk [96]. Data 
suggest that awareness of the risk of infections before and 
during glucocorticoid treatment is needed.
Both typical and atypical microorganisms can cause 
infections. Clinicians should realize that glucocorticoids 
Figure 3. Eff ects of infl ammation on bone. Processes stimulating bone growth (green arrows) and processes leading to bone loss (red arrows). 
The proinfl ammatory cytokine tumor necrosis factor alpha (TNFα) induces expression of Dickkopf-1 (Dkk-1) in synovial fi broblasts, which inhibits 
the Wnt signaling pathway. This results in decreased osteoblastogenesis and bone formation. Simultaneously, osteoclastic bone resorption is 
stimulated via receptor activator of nuclear factor-κB ligand (RANKL). Proinfl ammatory mediators stimulate osteoblasts to release macrophage 
colony-stimulating factor (M-CSF), stimulating osteoclastogenesis. Osteoprotegerin (OPG) is also released by osteoblasts and binds RANKL, thereby 
inhibiting osteoclastogenesis. RANK, receptor activator of nuclear factor-κB. Figure reproduced with permission from [130].
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may blunt classical clinical features of infection, and 
thereby delay the recognition of the infection and the 
start of treatment. Opportunistic infections with 
Pneumo cystis jiroveci have been reported for dosages 
from 16 mg prednisone equivalent daily during 8 weeks 
[100].
Th e performance of screening tests for infections, such 
as the tuberculin skin test and interferon gamma release 
assays, are suppressed by glucocorticoid therapy [101]. 
Furthermore, speciﬁ c recommendations for vaccination 




Th e risk of upper gastrointestinal tract bleeding or 
perforation increases about twofold with use of oral 
glucocorticoids or low-dose aspirin, and increases 
around fourfold with use of other NSAIDs [103]. Th is 
relatively high risk indicates that combined use of 
NSAIDs and glucocorticoids should be avoided, if 
possible [104]. If this combined treatment cannot be 
avoided, appropriate gastroprotective medication, such 
as proton pump inhibitors, helps to decrease the risk of 
bleeding and should be prescribed. In patients with low 
cardiovascular risk, cyclooxygenase-2 inhibitors may be 
an alternative for NSAIDs and proton pump inhibitors, 
since they induce a lower risk of gastrointestinal 
complications in RA compared with NSAIDs [105-107].
Other
Cases of bowel perforation and pancreatitis have been 
reported in the context of glucocorticoid use. However, 
causality between the glucocorticoid therapy and these 
events is unsure; other factors such as the inﬂ ammatory 
disease might also play a role.
Neuropsychiatric events
Slight increases in sense of well-being are frequently 
reported by patients starting glucocorticoid therapy. 
Symptoms of acathisia, insomnia and depression have 
also been recorded. Similar to the risk of osteonecrosis, 
the risk of psychosis seems to be a more frequent side 
eﬀ ect of pulse therapy in SLE patients compared with 
patients with RA [81]. Whether this increased incidence 
reﬂ ects an increased risk of this adverse eﬀ ect of 
glucocorticoids in SLE or whether – and to what extent – 
this increased incidence also reﬂ ects psychosis as a 
complication of the disease is uncertain.
Dermatologic problems
Easy bruising, ecchymoses, skin atrophy, striae, disturbed 
wound healing, acne and increased hair growth (exclud-
ing scalp hair) are undesirable dermatologic eﬀ ects that 
occur with glucocorticoid therapy [108]. Th e physician 
often considers these changes to be of minor clinical 
importance, but they may be disturbing to the patient. 
No reliable data on the occurrence of these adverse 
eﬀ ects are available.
Ophthalmologic eff ects
Posterior subcapsular cataract is a well-described 
complication of prolonged glucocorticoid use [109]. Th is 
type of cataract is also related to diabetes, but it is not 
typically age related. Cortical cataracts also have also 
been associated with glucocorticoid use.
Glucocorticoid-treated patients may develop mild 
increased intra-ocular pressure, which can lead to minor 
visual disturbances. Th e development of frank glaucoma, 
threatening eye sight, is rare for low-dose therapy, and 
tends to appear in patients who are otherwise pre-
disposed to the condition. A higher risk for glaucoma 
with glucocorticoids tends to occur more frequently if 
other risk factors are present, such as a family history of 
glaucoma, high myopia and diabetes [69]. In these 
patients, even when initiating low-dose therapy, an 
ophthalmologist should be consulted before the start of 
therapy [69].
Recommendations for clinical practice
Safe glucocorticoid therapy is glucocorticoid treatment 
with optimal therapeutic eﬀ ects and with minimal 
adverse eﬀ ects. To facilitate safe use, recommendations 
for the management of glucocorticoid therapy in 
rheumatic diseases have been developed and have been 
published in recent years [68-70]. Adverse eﬀ ects of 
glucocorticoids are partially avoidable. To avoid adverse 
events as much as possible, several measures can be 
taken.
Education
First, patients should be informed of what to expect from 
this therapy. Nowadays, patients are more articulate and 
stand up for themselves. Th ey should be actively in-
formed about the expectations on both positive and 
negative eﬀ ects of treatment with glucocorticoids. Th is 
information should be given over time, in small steps. 
Ideally, this should be supported by written information. 
Hopefully, this will lead to neutralizing of unfounded 
fears, earlier recognition of true adverse eﬀ ects, and 
patient compliance.
Preventive measures
Patients with or at risk of glucocorticoid-induced 
osteoporosis should receive appropriate preventive and/
or therapeutic interventions. In general, all patients 
starting glucocorticoid therapy at medium to high dose 
are at risk of developing osteoporosis. Calcium, (active) 
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vitamin D and bisphos phonates have been proven 
eﬀ ective in preventing and treating glucocorticoid-
induced osteoporosis [110-115]. Preven tive therapy with 
calcium and vitamin D should be started, because 
glucocorticoids impair bone mechanism – amongst other 
mechanisms – via inhibition of intestinal calcium absorp-
tion and renal tubular calcium reabsorption. Addition-
ally, in general, bisphosphonates are indicated. Guidelines 
on indications and choices for speciﬁ c drugs diﬀ er 
somewhat between countries.
Several algorithms have been developed to reﬁ ne the 
estimate of the risk of fractures for individual patients, 
such as the Fracture Risk in Glucocorticoid-induced 
Osteoporosis score, which includes the glucocorticoid 
dosage taken, and FRAX® fracture risk assessment 
[116-119], for which adjustments have also been 
suggested for glucocorticoid dosages >7.5 mg prednisone 
equivalent daily [120,121]. Th e decision of whether a 
patient should be treated depends on fracture risks and 
on the cost, eﬀ ectiveness and safety of the treatment.
Optimizing therapy
Th e initial dose, dose reduction and long-term dosing 
depend on the underlying rheumatic disease, disease 
activity, risk factors and individual responsiveness of the 
patient [68]. Except for treatment with glucocorticoids in 
early RA as a disease-modifying antirheumatic drug, in 
which dosages of 5 to 10  mg prednisone equivalent 
during 1 to 2 years are used, for prolonged treatment the 
glucocorticoid dosage should be kept to a minimum, and 
a glucocorticoid taper should be attempted in the case of 
remission or low disease activity; the reasons to continue 
glucocorticoid therapy should be regularly checked. Th e 
need for continuing glucocorticoid treatment should be 
under constant review, and the dose should be titrated 
against therapeutic response, risk of under treatment, and 
development of adverse eﬀ ects [70].
Optimal choices regarding the use of glucocorticoids in 
rheumatic diseases are patient speciﬁ c. Th e underlying 
disease, the presence of co-morbidity, the response to 
initial treatment, and the development of adverse eﬀ ects 
should inﬂ uence treatment decisions. Monitoring for 
adverse eﬀ ects should also be tailored to the patient: 
speciﬁ c aspects of individual patients may warrant a 
higher frequency of monitoring or a more comprehensive 
set of adverse eﬀ ects to be monitored. Continuously 
balancing the beneﬁ ts and risks of glucocorticoid therapy 
is recommended.
Use in pregnancy
Th e fetus is protected from maternal glucocorticoids 
since glucocorticoids bound to proteins cannot pass the 
placenta, and the enzyme 11β-hydroxysteroid dehydro-
ge nase in the placenta converts cortisol and prednisolone 
into the inactive 11-dehydro-prohormones. Th e 
prednisolone maternal-to-fetal blood concentration ratio 
is therefore about 10:1. Th e risk of adverse eﬀ ects of 
antenatal exposure to glucocorticoids such as reduced 
intrauterine growth and birth weight, neurocognitive 
adverse eﬀ ects and oral cleft seems dependent on the 
dose, preparation, duration of therapy and stage of 
pregnancy [122]. Avoiding high doses (such as 1 to 
2  mg/kg prednisone equivalent) is advised in the ﬁ rst 
trimester of pregnancy, whereas low to moderate doses 
of prednisone seem to be safe [122,123].
Future
New biological therapies have not replaced gluco corti-
coids, and probably will not replace them in the near 
future, as anchor drugs in therapeutic strategies for 
rheumatic diseases. Future research should therefore stay 
focused on the mechanisms causing beneﬁ cial and 
harmful eﬀ ects and on predictive factors for the eﬀ ects of 
glucocorticoids. Ultimately, response to glucocorticoids 
should preferably be predictable for the individual 
patient; studies on genomics and proteomics are being 
performed currently to this aim.
Apart from prediction of the treatment eﬀ ects, there is 
an ongoing quest for new glucocorticoids without 
potential to cause harmful eﬀ ects. Optimized gluco corti-
coids, such as selective glucocorticoid receptor agonists, 
are being developed to minimize the adverse eﬀ ects 
many patients experience, especially if glucocorticoids 
are given at higher dosages over longer periods of time 
[124]. Th e most important approach to optimize the 
risk–beneﬁ t ratio of glucocorticoids is to understand in 
more detail how the molecular mechanisms of genomic 
and nongenomic glucocorticoid actions – and their dose 
dependency – mediate the clinically wanted beneﬁ ts but 
also the known adverse eﬀ ects [125]. During past years, it 
has become evident that separation of the beneﬁ cial 
eﬀ ects from the harmful eﬀ ects is a more complicated 
process than anticipated [19,23]. Further research on this 
topic is ongoing [126], but a breakthrough for clinical 
practice will probably not occur within the next few 
years.
In some decades to come, we will hopefully be able to 
prescribe new drugs with glucocorticoid actions with an 
improved risk–beneﬁ t ratio. Moreover, it might be 
possible to adjust the use of glucocorticoids and other 
medication to speciﬁ c individual patients’ needs, 
characteristics and prognostic factors: personalized 
medicine. Th is would lead to a more eﬀ ective inhibition 
of the inﬂ ammatory diseases with less adverse eﬀ ects. 
While this has not been achieved, basic research on 
glucocorticoid eﬀ ects and detailed reports on therapeutic 
eﬃ  cacy and occurrence of adverse eﬀ ects will be valuable 
in weighing beneﬁ ts and risks in clinical practice.
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Conclusion
Glucocorticoids are very eﬀ ective anti-inﬂ ammatory and 
immunosuppressive drugs, but their use is restrained by 
fear for and occurrence of adverse eﬀ ects. Many of the 
adverse eﬀ ects can be avoided or dealt with when 
glucocorticoids are used prudently. Optimal choices 
regarding the use of glucocorticoids in rheumatic 
diseases are patient speciﬁ c, as is monitoring for adverse 
eﬀ ects. Th ere is an ongoing quest for new glucocorticoids 
without the potential to cause harmful eﬀ ects, such as 
selective glucocorticoid receptor agonists, but the 
application of a new compound in clinical practice will 
probably not occur within the next few years.
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